SCA
PETX

Secor Capital Advisors’s Aratana Therapeutics, Inc. PETX Stock Holding History

Secor Capital Advisors’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-17,097
Closed -$259K – 664
2015
Q2 		$259K Buy
+17,097
New +$247K 0.09% 328

Other funds holding PETX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Secor Capital Advisors's PETX Position: Q3 2015 in Review

Secor Capital Advisors sold out of Aratana Therapeutics, Inc. (PETX) in Q3 2015, closing a stake of 17,097 shares — an estimated $259K sold.

Secor Capital Advisors first reported a position in PETX in Q2 2015 and held it in 1 quarter. The position peaked at $259K in Q2 2015. 103 funds tracked by Wall St. Rank hold PETX as of Q3 2015.

  • Secor Capital Advisors reported no remaining Aratana Therapeutics, Inc. position as of Q3 2015 after selling out during the quarter.
  • Secor Capital Advisors sold 17,097 Aratana Therapeutics, Inc. shares in Q3 2015, an estimated $259K.
  • Secor Capital Advisors first reported a position in Aratana Therapeutics, Inc. in Q2 2015 and held it in 1 quarter.
  • Secor Capital Advisors's Aratana Therapeutics, Inc. position peaked at $259K in Q2 2015.
  • 103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q3 2015.

Based on Secor Capital Advisors's 13F filing for Q3 2015, filed 3 Nov 2015.